(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 33.08% in 21 sessions from $9.07 at 2023-02-23, to $6.07 at 15:29 EST on Friday, following the last session’s downward trend. NASDAQ is dropping 0.07% to $11,779.54, after four successive sessions in a row of gains.
Novavax’s last close was $5.76, 93.25% below its 52-week high of $85.37.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 90% and a drop 158.6% for the next.
Year-on-year quarterly revenue growth grew by 310.7%, now sitting on 1.85B for the twelve trailing months.
Novavax’s worth is way under its 50-day moving average of $9.75 and way below its 200-day moving average of $26.84.
Novavax’s sales growth is 72.4% for the ongoing quarter and negative 47.7% for the next.
More news about Novavax (NVAX).